Dario introduces glp-1 behavior change program to help achieve weight loss goals and better overall health outcomes

New program delivers whole health behavior change program to improve member health and deliver valuable insights to dario's partners new york , aug. 2, 2023 /prnewswire/ -- dariohealth corp. (nasdaq: drio) ("dario" or the "company"), a leader in the global digital health market, announced a new program today to deliver tailored behavior change support for individuals using glp-1s and other anti-obesity drugs. the new program will help members realize the transformational power of these new medications while improving overall health and potentially help dario's partners gain better insights on the impact across their populations.
DRIO Ratings Summary
DRIO Quant Ranking